daunorubicin


Also found in: Dictionary, Acronyms, Wikipedia.
Related to daunorubicin: doxorubicin

daunorubicin

 [daw″no-roo´bĭ-sin]
an antitumor antibiotic of the anthracycline family, produced by a strain of Streptomyces coeruleorubidus and having antimitotic, cytotoxic, and immunosuppressive effects. As the hydrochloride salt it is administered intravenously in the treatment of acute lymphoblastic leukemia and acute myelogenous leukemia. As a liposome-encapsulated preparation of the citrate salt, it is administered intravenously in the treatment of advanced Kaposi's sarcoma associated with acquired immunodeficiency syndrome (AIDS).

dau·no·ru·bi·cin

(daw'nō-rū'bi-sin),
An antineoplastic antibiotic of the rhodomycin group, obtained from Streptomyces peucetius.

daunorubicin

/dau·no·ru·bi·cin/ (daw″no-roo´bĭ-sin) an anthracycline (q.v.) antibiotic used as an antineoplastic; administered as the hydrochloride salt or as a liposome-encapsulated preparation of the citrate salt.

daunorubicin

Oncology An antineoplastic antibiotic isolated from Streptomyces spp, effective against ALL and AML, and used for other CAs Toxicity Dose-related BM suppression, mucositis, alopecia, severe local reaction with extravasation

ru·bid·o·my·cin

(rū-bid'ō-mī'sin)
An antibiotic used as an antineoplastic; similar to doxorubicin in antitumor activity and in exhibiting cumulative cardiotoxicity.
Synonym(s): daunorubicin.

daunorubicin

An antibiotic drug used in the consolidation phase of the treatment of acute leukaemia. The drug is on the WHO official list. Brand names are Cerubidin and Daunoxome.

dau·no·ru·bi·cin

(daw'nō-rū'bi-sin)
An anti neoplastic antibiotic of the rhodomycin group, obtained from Streptomyces peucetius.

daunorubicin

an anthracycline antibiotic produced by a strain of Streptomyces coeruleorubidus that is closely related to doxorubicin and has antimitotic, cytotoxic and immunosuppressive effects.
References in periodicals archive ?
Effects of curcumin, demethoxycurcumin and bisdemethoxycurcumin on daunorubicin transport across Caco-2 cell monolayer
The clinically utilized antineoplastic drug daunorubicin (Daunoblastin[R], Pharmacia) was ezploited as a cytotoxic reference compound.
Fluorescence Imaging Studies for the Disposition of Daunorubicin Liposomes (DaunoXome) within Tumor Tissue.
Cytarabine and daunorubicin have been a standard of care for the treatment of patients with acute myeloid leukemia (AML) for more than thirty years, and CPX-351 has demonstrated marked improvements in efficacy versus the conventional administration of the same two drugs in a randomized phase 2 clinical study in elderly patients with newly diagnosed AML.
The Company has announced positive results from its Phase 2 study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy (known as the "7+3" regimen) in patients with newly diagnosed acute myeloid leukemia.
The results were based on 12 months of follow-up in a randomized, Phase 2 trial that compared CPX-351 to conventional cytarabine and daunorubicin (the "7+3" regimen), the current standard of care (ASH Abstract #655).
Daunorubicin was prevented from accumulating in the leukemia cells due to an excess of P-glycoprotein in the cell, an efflux mechanism that does not affect Xanafide.
These in vitro studies, presented on April 13 and 14 at the American Association for Cancer Research (AACR) Annual meeting demonstrated how Xanafide acts differently from classical topoisomerase inhibitors such as daunorubicin.
The financial support provided by the LLS Therapy Acceleration Program (TAP) has been important in expediting the completion of the Phase 3, multicenter trial of CPX-351 versus conventional cytarabine plus daunorubicin in older patients with untreated high risk (secondary) AML.
The Phase 3 trial is designed as an open-label, randomized, active control, multi-center study of Xanafide in combination with cytarabine compared to daunorubicin in combination with cytarabine as initial remission induction therapy for patients with sAML.
Nasdaq: CPXX) today announced final induction response rate results (complete remission plus complete remission with incomplete hematologic recovery, or CR+CRi) in the Phase 3 study comparing CPX-351 (cytarabine:daunorubicin) liposome injection to the standard of care regimen, referred to as 7+3 (conventional cytarabine and daunorubicin treatment), in patients with untreated high-risk (secondary) acute myeloid leukemia (AML).
The trial compared CPX-351, a liposomal formulation of cytarabine and daunorubicin, which is designed to deliver a more optimal ratio of the drugs with less toxicity, to the standard combination of the two drugs.